.
Search
Dr. Dan Judge and Dr. C. Michael Gibson discuss new findings from a study evaluating the differential stabilization of transthyretin (TTR) with acoramidis and tafamidis. The study found greater TTR stabilization with acoramidis across multiple analyses, including in vitro testing of 51 patient samples representing 17 unique TTR variants.
Sponsored by an independent educational grant from BridgeBio Inc.
New insights into the heart-kidney connection in ATTR-CM. Dr. Jeffrey Testani and Dr. C. Michael Gibson discuss new analyses showing that acoramidis was associated with early and sustained kidney-protective effects in patients with ATTR-CM—findings that may help explain the therapy’s early cardiovascular benefits and offer new perspectives on cardiorenal health.
Supported by an independent educational grant from BridgeBio Inc.
Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.
The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]
Dr. Prem Soman and Dr. C. Michael Gibson Discuss: Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.